Table 1.
Patient characteristics at the moment of diagnosis with metastatic disease.
| Patient Characteristics | All Patients (n = 175) | Systemic Therapy (n = 67) | Local Therapy (n = 39) | Best Supportive Care (n = 69) | p-Value |
|---|---|---|---|---|---|
| Age | 0.001 | ||||
| Median, years (range) | 65 (29–89) | 61 (29–80) | 61 (41–80) | 69 (45–89) | |
| <65 years (%) | 86 (49.1) | 39 (58.2) | 25 (64.1) | 22 (31.9) | |
| >65 years (%) | 89 (50.9) | 28 (41.8) | 14 (35.9) | 47 (68.1) | |
| Gender (%) | 0.98 | ||||
| Male | 88 (50.3) | 34 (50.7) | 20 (51.3) | 34 (49.3) | |
| Female | 87 (49.7) | 33 (49.3) | 19 (48.7) | 35 (50.7) | |
| WHO performance score (%) | 0.000 | ||||
| 0 | 106 (60.6) | 55 (82.1) | 21 (53.8) | 30 (60.6) | |
| 1 | 25 (14.3) | 7 (10.4) | 3 (7.7) | 15 (21.7) | |
| 2 | 11 (6.3) | 2 (3) | 1 (2.6) | 8 (11.6) | |
| 3 | 3 (1.7) | 0 | 0 | 3 (4.3) | |
| 4 | 1 (0.6) | 0 | 0 | 1 (1.4) | |
| Unknown | 29 (16.6) | 3 (4,5) | 14 (35,9) | 12 (17.4) | |
| Median time from diagnosis primary tumor to stage IV | 0.02 * | ||||
| months (range) | 38 (0–477) | 43 (0–296) | 29 (0–477) | 42 (0–361) | |
| Brain metastases (%) | 0.75 | ||||
| No | 169 (96.6) | 64 (95.5) | 39 (100) | 66 (95.7) | |
| Yes | 3 (1.7) | 2 (3) | 0 | 1 (1.4) | |
| Unknown | 3 (1.7) | 1 (1.5) | 0 | 2 (2.9) | |
| Liver metastases (%) | 0.10 | ||||
| No | 20 (11.4) | 11 (16.4) | 1 (2.6) | 8 (11.6) | |
| Yes | 154 (88) | 56 (83.6) | 38 (97.4) | 60 (87) | |
| Unknown | 1 (0.6) | 0 | 0 | 1 (1.4) | |
| Metastatic sites (%) | 0.002 | ||||
| <3 metastatic sites | 134 (76.6) | 44 (65.7) | 39 (100) | 52 (75.4) | |
| >3 metastatic sites | 31 (17.7) | 18 (26.9) | 0 | 13 (18.8) | |
| Unknown | 10 (5.7) | 5 (7.5) | 0 | 4 (5.8) | |
| LDH (%) | 0.000 | ||||
| Not elevated | 81 (46.3) | 37 (55.2) | 26 (66.7) | 18 (26.1) | |
| Elevated (250–500) | 34 (19.4) | 12 (17.9) | 9 (23.1) | 13 (18.8) | |
| Elevated (>500) | 51 (29.1) | 17 (25.4) | 1 (2.6) | 33 (47.8) | |
| Unknown | 9 (5.1) | 1 (1.5) | 3 (7.7) | 5 (7.2) |
* A rank-sum test for the median time from diagnosis to stage IV disease was used to test the difference between groups of patients. WHO performance score: World-Health Organization performance score. LDH: lactate dehydrogenase.